What drives willingness to receive a new vaccine that prevents an emerging infectious disease? A discrete choice experiment among university students in Uganda.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
05
2021
accepted:
21
04
2022
entrez:
19
5
2022
pubmed:
20
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
There is a critical need to identify the drivers of willingness to receive new vaccines against emerging and epidemic diseases. A discrete choice experiment is the ideal approach to evaluating how individuals weigh multiple attributes simultaneously. We assessed the degree to which six attributes were associated with willingness to be vaccinated among university students in Uganda. We conducted a single-profile discrete choice experiment at Makerere University in 2019. Participants were asked whether or not they would be vaccinated in 8 unique scenarios where attributes varied by disease risk, disease severity, advice for or against vaccination from trusted individuals, recommendations from influential figures, whether the vaccine induced indirect protection, and side effects. We calculated predicted probabilities of vaccination willingness using mixed logistic regression models, comparing health professional students with all other disciplines. Of the 1576 participants, 783 (49.8%) were health professional students and 685 (43.5%) were female. Vaccination willingness was high (78%), and higher among health students than other students. We observed the highest vaccination willingness for the most severe disease outcomes and the greatest exposure risks, along with the Minister of Health's recommendation or a vaccine that extended secondary protection to others. Mild side effects and recommendations against vaccination diminished vaccination willingness. Our results can be used to develop evidence-based messaging to encourage uptake for new vaccines. Future vaccination campaigns, such as for COVID-19 vaccines in development, should consider acknowledging individual risk of exposure and disease severity and incorporate recommendations from key health leaders.
Sections du résumé
BACKGROUND
There is a critical need to identify the drivers of willingness to receive new vaccines against emerging and epidemic diseases. A discrete choice experiment is the ideal approach to evaluating how individuals weigh multiple attributes simultaneously. We assessed the degree to which six attributes were associated with willingness to be vaccinated among university students in Uganda.
METHODS
We conducted a single-profile discrete choice experiment at Makerere University in 2019. Participants were asked whether or not they would be vaccinated in 8 unique scenarios where attributes varied by disease risk, disease severity, advice for or against vaccination from trusted individuals, recommendations from influential figures, whether the vaccine induced indirect protection, and side effects. We calculated predicted probabilities of vaccination willingness using mixed logistic regression models, comparing health professional students with all other disciplines.
FINDINGS
Of the 1576 participants, 783 (49.8%) were health professional students and 685 (43.5%) were female. Vaccination willingness was high (78%), and higher among health students than other students. We observed the highest vaccination willingness for the most severe disease outcomes and the greatest exposure risks, along with the Minister of Health's recommendation or a vaccine that extended secondary protection to others. Mild side effects and recommendations against vaccination diminished vaccination willingness.
INTERPRETATION
Our results can be used to develop evidence-based messaging to encourage uptake for new vaccines. Future vaccination campaigns, such as for COVID-19 vaccines in development, should consider acknowledging individual risk of exposure and disease severity and incorporate recommendations from key health leaders.
Identifiants
pubmed: 35587501
doi: 10.1371/journal.pone.0268063
pii: PONE-D-21-15315
pmc: PMC9119467
doi:
Substances chimiques
COVID-19 Vaccines
0
Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0268063Subventions
Organisme : NIAID NIH HHS
ID : R01 AI132496
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
N Engl J Med. 2020 May 21;382(21):1969-1973
pubmed: 32227757
Vaccine. 2014 Nov 20;32(49):6649-54
pubmed: 25280436
Vaccine. 2006 Mar 15;24(12):2094-101
pubmed: 16332402
Vaccine. 2019 Nov 15;37(48):7190-7200
pubmed: 28890191
Vaccine. 2017 May 9;35(20):2676-2684
pubmed: 28408120
Vaccine. 2019 Apr 3;37(15):2079-2089
pubmed: 30857931
Vaccine. 2017 Jan 23;35(4):508-512
pubmed: 28040206
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
J Public Health (Oxf). 2017 Dec 1;39(4):e242-e250
pubmed: 27679662
Health Econ. 2009 Mar;18(3):321-36
pubmed: 18651601
Psychol Sci Public Interest. 2017 Dec;18(3):149-207
pubmed: 29611455
BMC Med Res Methodol. 2016 Apr 21;16:45
pubmed: 27098746
PLoS Negl Trop Dis. 2015 Jun 15;9(6):e0003838
pubmed: 26076007
PLoS One. 2014 Jul 24;9(7):e102505
pubmed: 25057914
Clin Microbiol Infect. 2017 May;23(5):279-280
pubmed: 27851999
Hum Vaccin Immunother. 2019;15(5):1080-1091
pubmed: 30735474
Value Health. 2011 Jun;14(4):403-13
pubmed: 21669364
Afr Health Sci. 2012 Dec;12(4):579-83
pubmed: 23516123
Vaccine. 2018 Mar 7;36(11):1467-1476
pubmed: 29426662
PLoS One. 2017 Jul 26;12(7):e0181073
pubmed: 28746348
Soc Sci Med. 2019 May;228:181-193
pubmed: 30925392
Value Health. 2019 Feb;22(2):157-160
pubmed: 30711059
PLoS One. 2018 Dec 7;13(12):e0208601
pubmed: 30532274
Vaccine. 2016 Dec 20;34(52):6700-6706
pubmed: 27810314
MMWR Morb Mortal Wkly Rep. 2015 Jul 10;64(26):714-8
pubmed: 26158352
NPJ Vaccines. 2020 Jun 15;5(1):51
pubmed: 32566261
Vaccine. 2016 Apr 4;34(15):1767-72
pubmed: 26928073
Vaccine. 2014 Apr 17;32(19):2150-9
pubmed: 24598724
Health Educ Res. 1992 Mar;7(1):107-16
pubmed: 10148735
Patient. 2015 Oct;8(5):373-84
pubmed: 25726010
EBioMedicine. 2016 Oct;12:295-301
pubmed: 27658738
Euro Surveill. 2016 Jun 2;21(22):
pubmed: 27277581
Health Econ. 2012 Jun;21(6):730-41
pubmed: 21557381
BMC Public Health. 2017 Aug 7;17(1):642
pubmed: 28784109
Health Educ Q. 1984 Spring;11(1):1-47
pubmed: 6392204
Lancet Infect Dis. 2017 Aug;17(8):867-872
pubmed: 28545721